Due to begin operations in late September, TEC will bring value-added laboratory services to the heart of the biotech community
Italian-based Stevanato Group, a leading producer of pharmaceutical glass containers and integrated provider of drug delivery systems, is preparing to open its Technology Excellence Center in Boston (US TEC), Massachusetts.
The new center will provide a full-service approach to support biopharmas along their drug development journey, from the early phase to commercialization and lifecycle management.
With its 70-year expertise in glass primary container manufacturing, Stevanato Group can count on an exceptional amount of knowledge in glass primary packaging design and technology. Since 2013, an interdisciplinary team of researchers and scientists in Italy have been conducting a wide range of testing, from container performance to chemical analysis. Through the years, the company also strengthened its analytical capabilities with a network of collaborators and partnerships, such as with Pfeiffer Vacuum for Container Closure Integrity Testing.
To respond to the growing demand in US biologics for integrated analytical offerings and project management services, Stevanato Group is establishing a Boston-based laboratory and Technology Excellence Center.
Set to open its doors in late September, US TEC will support biopharma drug development throughout the lifecycle, helping them overcome the challenges of the container-closure system.
The technology and knowledge transfer from the Italian laboratory will be finalized in the fall. Leveraging the Group's extensive knowledge in material science of glass, plastics, and rubber, US TEC will support one of the most binding decisions for biopharma industry players: how to select the optimum glass container. Making the right choice during the early-stage of product development ensures two-fold compatibility: Drug and Container Closure System, as well as Container Closure System integration into drug delivery devices.
By partnering at an early stage, US TEC can anticipate challenges and present viable, well-informed solutions to its biopharma customers, saving development time and resources.
"R&D represents a key driver for Stevanato Group's growth. From its outset, the US TEC will advise on materials science, chemistry, and engineering performing many added value analytical tests focusing on container closure characterization as well as fill&finish development and optimization. In the second phase, we will be adding customized solutions dedicated to product development and functional testing of primary containers and drug delivery devices. Located in the cradle of biotech, US TEC can easily integrate within the product development team and the value chain of our local customers.", says Paolo Patri, Stevanato Group Chief Technology Officer.
To support today's increasingly urgent need for treatments and vaccines related to COVID-19, Stevanato Group has deployed all its available assets to ensure the availability of state-of-the-art glass vials and syringes, plastics diagnostic consumables, equipment, and analytical testing.
"As pharma companies are under pressure to find more effective and safer treatments rapidly, more clinical trials take place, and new emerging therapies are developed and tested. Being in the US, we can offer timely solutions for robust product development for these therapies. With our dedicated team of subject matter experts, we work as a single point of contact coordinating internal resources and our best-in-class network of partners and consultants", says Abizer Harianawala, Site Leader at Stevanato Group's US TEC.
About Stevanato Group:
Established in 1949, Stevanato Group is the world's largest, privately-owned designer and producer of glass primary packaging for the pharmaceutical industry. From its outset, the Group has developed its own glass converting technology to ensure the highest standards of quality. The Group comprises a wide set of capabilities dedicated to serving the biopharmaceutical and diagnostic industries: from glass containers with its historical brand Ompi, to high-precision plastic diagnostic and medical components, to contract manufacturing for drug delivery devices, to vision inspection systems, assembly, and packaging equipment. The Group also provides analytical and testing services to study container closure integrity and integration into drug delivery devices, streamlining the drug development process. Thanks to its unique approach as a one-stop-shop, Stevanato Group can offer an unprecedented set of solutions to biopharma companies for a faster time to market and a reduced total cost of ownership.
For more information, please visit www.stevanatogroup.com
